malondialdehyde has been researched along with Lymphoproliferative Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouafia, F; Coiffier, B; Drai, J; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C | 1 |
1 other study(ies) available for malondialdehyde and Lymphoproliferative Disorders
| Article | Year |
|---|---|
The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide.
Topics: Adult; Aged; Biomarkers; Cyclophosphamide; Erythrocytes; Female; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Malondialdehyde; Middle Aged; Regression Analysis; Superoxide Dismutase; Transplantation Conditioning | 2001 |